Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.49 |
| ▸ | SSTR4 | P31391 | 4/20 | 0.46 |
| ▸ | CTSS | P25774 | 2/20 | 0.44 |
| ▸ | RBP4 | P02753 | 5/20 | 0.42 |
| ▸ | TTR | P02766 | 4/20 | 0.42 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.42 |
| ▸ | BRAF | P15056 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RAF1 | P04049 | 2/20 | 0.41 |
| ▸ | ARAF | P10398 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11565480 | 0.88 | HPGD (0.46) | NR1H2CTSSRBP4TTRHPGD | |
| SCHEMBL13419711 | 0.83 | TLR9 (0.43) | — | |
| SCHEMBL444815 | 0.82 | NR1H2 (0.39) | NR1H2RBP4TTR | |
| SCHEMBL23373227 | 0.81 | SSTR1 (0.56) | SSTR4RBP4TTRSSTR1 | |
| SCHEMBL446531 | 0.81 | RBP4 (0.41) | RBP4 | |
| SCHEMBL272940 | 0.80 | SYK (0.49) | NR1H2BRAF | |
| SCHEMBL21644468 | 0.80 | PDPK1 (0.48) | — | |
| SCHEMBL6313905 | 0.80 | KDM4E (0.51) | — | |
| SCHEMBL4937786 | 0.80 | ACHE (0.49) | SSTR4CTSSRBP4TTRBRAF | |
| SCHEMBL24192366 | 0.79 | UTS2R (0.47) | NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105801584-B | Novel aryl amide Raf kinase and its preparation method and application | 中国药科大学 | 2019-03-05 | — | — | CN | disclosed |
| CN-105801584-A | Novel aromatic amide Raf kinase inhibitors and preparation method and application thereof | 中国药科大学 | 2016-07-27 | — | — | CN | disclosed |
| US-20080312192-A1 | Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases | BOLD GUIDO | 2008-12-18 | — | — | US | disclosed |
| US-20080312192-A1 | Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases | BOLD GUIDO | 2008-12-18 | — | — | US | disclosed |
| US-20080312192-A1 | Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases | BOLD GUIDO | 2008-12-18 | — | — | US | disclosed |
| EP-1689376-A2 | DIARYL UREA DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005051366-A2 | DIARYL UREA DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312192-A1 | Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases | RET, PRKDC, PRKACA | NR1H2 4001/4885SSTR4 3262/4885CTSS 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.